Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 8 |
| 1.1 List of Tables | 5 | 3 |
| 1.2 List of Figures | 8 | 3 |
| 2 Global Musculoskeletal Disorders Therapeutics Market: Introduction | 11 | 2 |
| 2.1 GBI Research Report Guidance | 12 | 1 |
| 3 Global Musculoskeletal Disorders Therapeutics Market: Market Overview | 13 | 9 |
| 3.1 Introduction | 13 | 1 |
| 3.2 Revenue Forecasts for the Global Musculoskeletal Disorders Therapeutics Market | 14 | 1 |
| 3.2.1 Revenue | 14 | 1 |
| 3.2.2 Annual Cost of Treatment (ACT) | 15 | 1 |
| 3.2.3 Treatment Usage Patterns | 16 | 1 |
| 3.2.3.1 Diseased Population | 17 | 1 |
| 3.2.3.2 Treatment Seeking Population | 18 | 1 |
| 3.2.3.3 Diagnosis Population | 19 | 1 |
| 3.2.3.4 Prescription Population | 20 | 1 |
| 3.3 Generics in Musculoskeletal Disorders Therapeutics Market | 21 | 1 |
| 4 Global Musculoskeletal Disorders Therapeutics Market: Geographical Landscape | 22 | 31 |
| 4.1 Revenue Analysis By Geography | 22 | 2 |
| 4.2 The US | 24 | 1 |
| 4.2.1 Revenue | 24 | 2 |
| 4.2.2 Annual Cost of Treatment | 26 | 2 |
| 4.2.3 Treatment Usage Patterns | 28 | 2 |
| 4.2.3.1 Diseased Population | 30 | 1 |
| 4.2.3.2 Treatment Seeking Population | 31 | 1 |
| 4.2.3.3 Diagnosis Population | 32 | 1 |
| 4.2.3.4 Prescription Population | 33 | 1 |
| 4.3 Top Five EU Countries | 34 | 1 |
| 4.3.1 Revenue | 34 | 2 |
| 4.3.2 Annual Cost of Treatment | 36 | 2 |
| 4.3.3 Treatment Usage Patterns | 38 | 2 |
| 4.3.3.1 Diseased Population | 40 | 1 |
| 4.3.3.2 Treatment Seeking Population | 41 | 1 |
| 4.3.3.3 Diagnosis Population | 42 | 1 |
| 4.3.3.4 Prescription Population | 43 | 1 |
| 4.4 Japan | 44 | 1 |
| 4.4.1 Revenue | 44 | 2 |
| 4.4.2 Annual Cost of Treatment | 46 | 1 |
| 4.4.3 Treatment Usage Patterns | 47 | 2 |
| 4.4.3.1 Diseased Population | 49 | 1 |
| 4.4.3.2 Treatment Seeking Population | 50 | 1 |
| 4.4.3.3 Diagnosis Population | 51 | 1 |
| 4.4.3.4 Prescription Population | 52 | 1 |
| 5 Global Musculoskeletal Disorders Therapeutics Market: Therapeutic Landscape | 53 | 49 |
| 5.1 Osteoporosis Therapeutics Market | 53 | 1 |
| 5.1.1 Introduction | 53 | 1 |
| 5.1.2 Revenue | 53 | 2 |
| 5.1.3 Annual Cost of Treatment | 55 | 2 |
| 5.1.4 Treatment Usage Patterns | 57 | 3 |
| 5.1.4.1 Diseased Population | 60 | 1 |
| 5.1.4.2 Treatment Seeking Population | 61 | 1 |
| 5.1.4.3 Diagnosis Population | 62 | 1 |
| 5.1.4.4 Prescription Population | 63 | 1 |
| 5.1.5 Drivers and Barriers for the Osteoporosis Therapeutics Market | 64 | 1 |
| 5.1.5.1 Drivers for the Osteoporosis Therapeutics Market | 65 | 1 |
| 5.1.5.2 Barriers for the Osteoporosis Therapeutics Market | 65 | 1 |
| 5.1.6 Opportunity and Unmet Need | 65 | 1 |
| 5.2 Osteoarthritis Therapeutics Market | 66 | 1 |
| 5.2.1 Introduction | 66 | 1 |
| Revenue | 66 | 2 |
| 5.2.3 Annual Cost of Treatment | 68 | 1 |
| 5.2.4 Treatment Usage Patterns | 69 | 3 |
| 5.2.4.1 Diseased Population | 72 | 1 |
| 5.2.4.2 Treatment Seeking Population | 73 | 1 |
| 5.2.4.3 Diagnosis Population | 74 | 1 |
| 5.2.4.4 Prescription Population | 75 | 1 |
| 5.2.5 Drivers and Barriers for the Osteoarthritis Therapeutics Market | 76 | 1 |
| 5.2.5.1 Drivers for the Osteoarthritis Therapeutics Market | 77 | 1 |
| 5.2.5.2 Barriers for the Osteoarthritis Therapeutics Market | 77 | 1 |
| 5.2.6 Opportunity and Unmet Need | 77 | 1 |
| 5.3 Rheumatoid Arthritis Therapeutics Market | 78 | 1 |
| 5.3.1 Introduction | 78 | 1 |
| Revenue | 78 | 2 |
| 5.3.3 Annual Cost of Treatment | 80 | 2 |
| 5.3.4 Treatment Usage Patterns | 82 | 2 |
| 5.3.4.1 Diseased Population | 84 | 1 |
| 5.3.4.2 Treatment Seeking Population | 85 | 1 |
| 5.3.4.3 Diagnosis Population | 86 | 1 |
| 5.3.4.4 Prescription Population | 87 | 1 |
| 5.3.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market | 88 | 1 |
| 5.3.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market | 88 | 1 |
| 5.3.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market | 88 | 1 |
| 5.3.6 Unmet Need for Rheumatoid Arthritis Therapeutics Market | 89 | 1 |
| 5.4 Muscular Dystrophy Therapeutics Market | 90 | 1 |
| 5.4.1 Introduction | 90 | 1 |
| 5.4.2 Revenue | 90 | 2 |
| 5.4.3 Annual Cost of Treatment | 92 | 1 |
| 5.4.4 Treatment Usage Patterns | 93 | 3 |
| 5.4.4.1 Diseased Population | 96 | 1 |
| 5.4.4.2 Treatment Seeking Population | 97 | 1 |
| 5.4.4.3 Diagnosis Population | 98 | 1 |
| 5.4.4.4 Prescription Population | 99 | 1 |
| 5.4.5 Drivers and Barriers for the Muscular Dystrophy Therapeutics Market | 100 | 1 |
| 5.4.5.1 Drivers for the Muscular Dystrophy Therapeutics Market | 100 | 1 |
| 5.4.5.2 Barriers for the Muscular Dystrophy Therapeutics Market | 101 | 1 |
| 5.4.6 Unmet Need for Muscular Dystrophy Therapeutics Market | 101 | 1 |
| 6 Global Musculoskeletal Disorders Therapeutics Market: Pipeline Analysis | 102 | 32 |
| Introduction | 102 | 1 |
| 6.1.1 Research and Development Pipeline Osteoarthritis | 103 | 6 |
| 6.1.2 Research and Development Pipeline Osteoporosis | 109 | 9 |
| 6.1.3 Research and Development Pipeline Rheumatoid Arthritis | 118 | 11 |
| 6.1.4 Research and Development Pipeline Muscular Dystrophy | 129 | 3 |
| 6.2 Profiles of Promising Drugs in the Musculoskeletal Disorders Therapeutics Market | 132 | 1 |
| Catena/Sovrima (Idebenone) | 132 | 1 |
| 6.2.1.1 Overview | 132 | 1 |
| 6.2.1.2 Efficacy | 132 | 1 |
| 6.2.1.3 Safety | 132 | 1 |
| 6.2.1.4 Clinical Study Details | 132 | 1 |
| 6.2.2 IPlex(TM) (Mecasermin Rinfabate) | 132 | 1 |
| 6.2.2.1 Overview | 132 | 1 |
| 6.2.2.2 Efficacy | 132 | 1 |
| 6.2.2.3 Safety | 132 | 1 |
| 6.2.2.4 Clinical Study Details | 132 | 1 |
| 6.2.3 CG5503 (Tapentadol ER) | 133 | 1 |
| 6.2.3.1 Overview | 133 | 1 |
| 6.2.3.2 Efficacy | 133 | 1 |
| 6.2.3.3 Safety | 133 | 1 |
| 6.2.3.4 Clinical Study Details | 133 | 1 |
| 7 Global Musculoskeletal Disorders Therapeutics Market: Competitive Landscape | 134 | 18 |
| 7.1 Evolving competitive landscape | 134 | 1 |
| 7.1.1 Major Players | 135 | 1 |
| 7.2 Market Share Analysis | 136 | 1 |
| 7.3 Competitive Profiling | 137 | 1 |
| 7.3.1 Novartis AG | 137 | 1 |
| 7.3.1.1 Company Overview | 137 | 1 |
| 7.3.1.2 Business Description | 137 | 1 |
| 7.3.1.3 Marketed Drugs | 138 | 1 |
| 7.3.2 Pfizer | 138 | 1 |
| 7.3.2.1 Company Overview | 138 | 1 |
| 7.3.2.2 Business Description | 139 | 1 |
| 7.3.2.3 Marketed Drugs | 139 | 1 |
| 7.3.3 Hoffmann-La Roche Ltd. | 139 | 1 |
| 7.3.3.1 Company Overview | 139 | 1 |
| 7.3.3.2 Business Description | 140 | 1 |
| 7.3.3.3 Marketed Drugs | 140 | 1 |
| 7.3.4 Merck &Co., Inc | 141 | 1 |
| 7.3.4.1 Company Overview | 141 | 1 |
| 7.3.4.2 Business Description | 141 | 1 |
| 7.3.4.3 Marketed Drugs | 141 | 2 |
| 7.3.5 Eli Lilly and Company | 143 | 1 |
| 7.3.5.1 Company Overview | 143 | 1 |
| 7.3.5.2 Business Description | 143 | 1 |
| 7.3.5.3 Marketed Drugs | 143 | 2 |
| 7.3.6 Abbott Laboratories | 145 | 1 |
| 7.3.6.1 Company Overview | 145 | 1 |
| 7.3.6.2 Business Description | 145 | 1 |
| 7.3.6.3 Marketed Drugs | 145 | 1 |
| 7.3.7 Johnson &Johnson | 146 | 1 |
| 7.3.7.1 Company Overview | 146 | 1 |
| 7.3.7.2 Business Description | 146 | 1 |
| 7.3.7.3 Marketed Drugs | 147 | 1 |
| 7.3.8 Amgen Inc. | 147 | 1 |
| 7.3.8.1 Company Overview | 147 | 1 |
| 7.3.8.2 Business Description | 147 | 1 |
| 7.3.8.3 Marketed Drugs | 148 | 1 |
| 7.3.9 Procter &Gamble Company | 149 | 1 |
| 7.3.9.1 Company Overview | 149 | 1 |
| 7.3.9.2 Business Description | 149 | 1 |
| 7.3.9.3 Marketed Drugs | 149 | 1 |
| 7.3.10 Bristol-Myers Squibb Company | 150 | 1 |
| 7.3.10.1 Company Overview | 150 | 1 |
| 7.3.10.2 Business Description | 150 | 1 |
| 7.3.10.3 Marketed Drugs | 150 | 2 |
| 8 Global Musculoskeletal Disorders Therapeutics Market: M&A Landscape | 152 | 11 |
| 8.1 Overview | 152 | 1 |
| 8.1.1 Pfizer Acquires Wyeth | 153 | 1 |
| 8.1.2 Cephalon Acquires Arana Therapeutics | 153 | 1 |
| 8.1.3 Aspen Pharmacare Acquires Sigma Pharmaceuticals | 153 | 1 |
| 8.2 R&D Licensing Agreements | 153 | 1 |
| 8.2.1 Deals by Phase | 153 | 1 |
| Deals by Geography | 154 | 1 |
| 8.2.3 Deals by Value ($) | 155 | 1 |
| 8.2.4 Preclinical | 156 | 1 |
| 8.2.4.1 RDEA119 | 156 | 1 |
| 8.2.4.2 BGC 945 | 156 | 1 |
| 8.2.4.3 Astex FGFr Inhibitor Program | 156 | 1 |
| 8.2.4.4 DX-2240 | 157 | 1 |
| 8.2.5 Phase I | 157 | 1 |
| 8.2.5.1 BTT-1023 | 157 | 1 |
| 8.2.5.2 PG110 | 157 | 1 |
| 8.2.5.3 Sodium Pentosan Polysulfate | 158 | 1 |
| 8.2.6 Phase II | 158 | 1 |
| 8.2.6.1 ALD518 | 158 | 1 |
| 8.2.7 Phase III | 159 | 1 |
| 8.2.7.1 Calcitonin | 159 | 1 |
| 8.2.8 Approved | 160 | 1 |
| 8.2.8.1 Pennsaid and Pennsaid Plus | 161 | 1 |
| 8.2.8.2 Voltaren Gel | 161 | 1 |
| 8.2.8.3 DW-1350 | 161 | 1 |
| 8.2.9 Marketed Drugs | 162 | 1 |
| 8.2.9.1 Calcitonin | 162 | 1 |
| 8.2.9.2 Fosteum | 162 | 1 |
| 9 Global Musculoskeletal Disorders Therapeutics Market: Appendix | 163 | 7 |
| 9.1 Market Definitions | 163 | 1 |
| 9.2 Abbreviations | 163 | 2 |
| 9.3 Research Methodology | 165 | 5 |
| 9.3.1 Coverage | 165 | 1 |
| 9.3.2 Secondary Research | 165 | 1 |
| 9.3.3 Primary Research | 166 | 1 |
| 9.3.4 Forecasts | 166 | 1 |
| 9.3.4.1 Epidemiology-based Forecasting | 166 | 3 |
| 9.3.5 Expert Panel Validation | 169 | 1 |
| 9.4 Contact Us | 169 | 1 |
| 9.5 Disclaimer | 169 | 1 |
| 9.6 Sources | 169 | 1 |